Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
XEN1101 Proof of Concept in MDD
NCT04827901Phase 2Completed
- Start
- Oct 2021
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of azetukalner in major depressive disorder (MDD). Started Oct 2021; status: completed.
02
Drugs
azetukalner
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT04827901.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04827901.